Quick Answer
Organon & Co. reported Common Stock Shares Outstanding of 260.32 million shares for the year ending 2025.
- Organon & Co. showed an increase of +1.0% in Common Stock Shares Outstanding from 2024 to 2025.
- This data is from Organon & Co.'s annual report (Form 10-K), filed with the SEC on February 24, 2026.
- XBRL data for this metric is available from 2021 to 2025 (5 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q2 2021: 253.52 million shares | Q3 2021: 253.55 million shares | Q1 2022: 253.64 million shares | Q2 2022: 254.32 million shares | Q3 2022: 254.36 million shares | Q1 2023: 254.43 million shares | Q2 2023: 255.57 million shares | Q3 2023: 255.61 million shares | Q1 2024: 255.85 million shares | Q2 2024: 257.47 million shares | Q3 2024: 257.54 million shares | Q1 2025: 257.95 million shares | Q2 2025: 259.97 million shares | Q3 2025: 259.98 million shares.
- Over the full 5 years of available data (2021 to 2025), Organon & Co.'s Common Stock Shares Outstanding has grown by 2.7%.
- Historical annual values: Fiscal year 2025: 260.32 million shares | Fiscal year 2024: 257.80 million shares | Fiscal year 2023: 255.63 million shares | Fiscal year 2022: 254.37 million shares | Fiscal year 2021: 253.55 million shares.
- Data sourced from SEC EDGAR public filings as of August 10, 2026.
Last verified: